To exclude that the observed association between ctDNA levels and treatment response was due to the specific activity of KRAS mutations, the PFS and OS comparing presence (n = 78) or absence (n = 22) of KRAS mutations in the pretreatment tumor tissue were evaluated. Here, KRAS is linked to neoplasm.